WO2002062330A3 - Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs - Google Patents

Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs Download PDF

Info

Publication number
WO2002062330A3
WO2002062330A3 PCT/EP2002/000946 EP0200946W WO02062330A3 WO 2002062330 A3 WO2002062330 A3 WO 2002062330A3 EP 0200946 W EP0200946 W EP 0200946W WO 02062330 A3 WO02062330 A3 WO 02062330A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
treatment
rejection reactions
salts
transplanted organs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/000946
Other languages
French (fr)
Other versions
WO2002062330A2 (en
Inventor
Riccardo Bertini
Francesco Colotta
Roberto Novellini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe SpA
Original Assignee
Dompe SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ526655A priority Critical patent/NZ526655A/en
Priority to AT02719742T priority patent/ATE304846T1/en
Priority to KR1020037009714A priority patent/KR100857898B1/en
Priority to EP02719742A priority patent/EP1355641B1/en
Priority to JP2002562337A priority patent/JP2004517948A/en
Priority to SK973-2003A priority patent/SK287632B6/en
Priority to PL363576A priority patent/PL215109B1/en
Priority to DK02719742T priority patent/DK1355641T3/en
Priority to AU2002250869A priority patent/AU2002250869B2/en
Priority to BRPI0206804A priority patent/BRPI0206804B1/en
Priority to MXPA03006686A priority patent/MXPA03006686A/en
Priority to EEP200300340A priority patent/EE05233B1/en
Priority to DE60206245T priority patent/DE60206245T2/en
Priority to CA002432432A priority patent/CA2432432C/en
Priority to HU0303024A priority patent/HU229070B1/en
Priority to BR0206804-4A priority patent/BR0206804A/en
Application filed by Dompe SpA filed Critical Dompe SpA
Publication of WO2002062330A2 publication Critical patent/WO2002062330A2/en
Priority to US10/250,465 priority patent/US7560487B2/en
Publication of WO2002062330A3 publication Critical patent/WO2002062330A3/en
Priority to NO20033273A priority patent/NO334285B1/en
Priority to IL157180A priority patent/IL157180A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

The use of (R).-ibuprofen methanesulfonamide is described for the preparation of medicaments for the treatment and prevention of functional injury resulting from rejection reactions of transplanted organs. In particular, the use of non-toxic salts of (R)-ibuprofen methanesulfonamide, such as the (L)-lysine salt, is described for the prevention and the treatment of rejection reactions of transplanted kidneys.
PCT/EP2002/000946 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs Ceased WO2002062330A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
MXPA03006686A MXPA03006686A (en) 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs.
KR1020037009714A KR100857898B1 (en) 2001-02-02 2002-01-30 (R) -Ibuprofen methanesulfonamide and its salts for the treatment and prevention of rejection of transplanted organs
EP02719742A EP1355641B1 (en) 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
JP2002562337A JP2004517948A (en) 2001-02-02 2002-01-30 Use of (R) -ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of transplant rejection
SK973-2003A SK287632B6 (en) 2001-02-02 2002-01-30 Use of (R)-ibuprofen methanesulfonamide and salts thereof
AT02719742T ATE304846T1 (en) 2001-02-02 2002-01-30 USE OF R-IBUPROFEN METHANESULFONAMID AND ITS SALTS FOR THE TREATMENT AND PREVENTION OF REJECTION REACTIONS IN TRANSPLARTED ORGANS
DK02719742T DK1355641T3 (en) 2001-02-02 2002-01-30 Use of (R) -ibuprofen-methanesulfonamide and its salts in the treatment and prevention of rejection reactions in transplanted organs
AU2002250869A AU2002250869B2 (en) 2001-02-02 2002-01-30 Use of (R)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
BRPI0206804A BRPI0206804B1 (en) 2001-02-02 2002-01-30 use of (r) -ibuprofen methanesulfonamide and its salts in the treatment and prevention of functional injury resulting from transplanted organ rejection reactions
EEP200300340A EE05233B1 (en) 2001-02-02 2002-01-30 Use of (R) -ibuprofen methanesulfonamide or a salt thereof for the manufacture of a medicament for the financing or treatment of ischemia / reperfusion injury of transplanted organs
PL363576A PL215109B1 (en) 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
NZ526655A NZ526655A (en) 2001-02-02 2002-01-30 Use of (R)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
CA002432432A CA2432432C (en) 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
HU0303024A HU229070B1 (en) 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof for the preparation of pharmaceutical composition useful in the treatment and prevention of rejection reactions of transplanted organs
BR0206804-4A BR0206804A (en) 2001-02-02 2002-01-30 Use of (r) -ibuprofen methanesulfonamide and its salts in the treatment and prevention of organ transplant rejection
DE60206245T DE60206245T2 (en) 2001-02-02 2002-01-30 USE OF R-IBUPROFEN METHANESULPHONAMIDE AND ITS SALTS FOR THE TREATMENT AND PREVENTION OF DISPOSAL REACTIONS IN TRANSPLANTED ORGANS
US10/250,465 US7560487B2 (en) 2001-02-02 2003-01-30 Use of (R)—ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
NO20033273A NO334285B1 (en) 2001-02-02 2003-07-18 Use of (R) -ibuprofen-methanesulfonamide and its salts for the treatment and prevention of rejection of transplanted organs
IL157180A IL157180A (en) 2001-02-02 2003-07-31 Use of (r)-ibuprofen methanesulfonamide and salts thereof for the preparation of medicaments for the treatment and prevention of rejection reactions of transplanted organs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2001A000206 2001-02-02
IT2001MI000206A ITMI20010206A1 (en) 2001-02-02 2001-02-02 USE OF (R) -IBUPROFENE METHANE SULPHONAMIDE AND ITS NON-TOXIC SALTS FOR THE PREPARATION OF MEDICATIONS FOR TREATMENT AND PREVENTION

Publications (2)

Publication Number Publication Date
WO2002062330A2 WO2002062330A2 (en) 2002-08-15
WO2002062330A3 true WO2002062330A3 (en) 2003-04-03

Family

ID=11446717

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000946 Ceased WO2002062330A2 (en) 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs

Country Status (26)

Country Link
US (1) US7560487B2 (en)
EP (1) EP1355641B1 (en)
JP (1) JP2004517948A (en)
KR (1) KR100857898B1 (en)
CN (1) CN1561205A (en)
AT (1) ATE304846T1 (en)
AU (1) AU2002250869B2 (en)
BR (2) BRPI0206804B1 (en)
CA (1) CA2432432C (en)
CZ (1) CZ303665B6 (en)
DE (1) DE60206245T2 (en)
DK (1) DK1355641T3 (en)
EE (1) EE05233B1 (en)
ES (1) ES2248541T3 (en)
HU (1) HU229070B1 (en)
IL (1) IL157180A (en)
IT (1) ITMI20010206A1 (en)
MX (1) MXPA03006686A (en)
NO (1) NO334285B1 (en)
NZ (1) NZ526655A (en)
PL (1) PL215109B1 (en)
PT (1) PT1355641E (en)
RU (1) RU2257895C2 (en)
SK (1) SK287632B6 (en)
WO (1) WO2002062330A2 (en)
ZA (1) ZA200304861B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9556115B2 (en) 2009-10-06 2017-01-31 Dompé Farmaceutici S.P.A. Sulfonamides for the prevention of diabetes

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004003673T2 (en) * 2004-03-25 2007-10-04 Dompe' Pha.R.Ma S.P.A. Use of N- (2-aryl-propionyl) -sulfonamides for the treatment of spinal cord injuries
WO2006121995A2 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
CA2669935A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America, Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
EP2308484A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
JP5978216B2 (en) 2010-09-10 2016-08-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Methods for combination therapy of theophylline and febuxostat
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
HUE065802T2 (en) * 2017-03-15 2024-06-28 Numares Ag Use of a marker set for determining the risk of kidney rejection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024710A1 (en) * 1998-10-23 2000-05-04 Dompe' S.P.A. N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879283A (en) * 1985-10-03 1989-11-07 Wisconsin Alumni Research Foundation Solution for the preservation of organs
RU2008901C1 (en) * 1991-03-29 1994-03-15 Донецкий государственный медицинский институт им.М.Горького Method for pharmacological protection of decentralized kidney
ATE257389T1 (en) * 1992-09-17 2004-01-15 Amgen Inc PHARMACEUTICAL COMPOSITIONS CONTAINING INTERLEUKIN-1 INHIBITORS
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
JPH08231413A (en) * 1994-12-29 1996-09-10 Mochida Pharmaceut Co Ltd Prophylactic / therapeutic agent for diseases caused by organ disorders
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024710A1 (en) * 1998-10-23 2000-05-04 Dompe' S.P.A. N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI L ET AL: "The relationship between cytokines in MLC supernatants and acute rejection after renal transplantation.", TRANSPLANTATION PROCEEDINGS. UNITED STATES NOV 2000, vol. 32, no. 7, November 2000 (2000-11-01), pages 2531 - 2534, XP002223824, ISSN: 0041-1345 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9556115B2 (en) 2009-10-06 2017-01-31 Dompé Farmaceutici S.P.A. Sulfonamides for the prevention of diabetes

Also Published As

Publication number Publication date
PL363576A1 (en) 2004-11-29
EE05233B1 (en) 2009-12-15
ZA200304861B (en) 2004-06-30
IL157180A (en) 2009-06-15
RU2003126600A (en) 2005-02-27
MXPA03006686A (en) 2004-05-31
NO20033273D0 (en) 2003-07-18
ES2248541T3 (en) 2006-03-16
PT1355641E (en) 2005-11-30
HU229070B1 (en) 2013-07-29
SK9732003A3 (en) 2003-11-04
BRPI0206804B1 (en) 2018-09-25
US7560487B2 (en) 2009-07-14
CA2432432A1 (en) 2002-08-15
HUP0303024A2 (en) 2003-12-29
DE60206245T2 (en) 2006-06-14
NO20033273L (en) 2003-07-18
SK287632B6 (en) 2011-04-05
NO334285B1 (en) 2014-01-27
WO2002062330A2 (en) 2002-08-15
EP1355641B1 (en) 2005-09-21
NZ526655A (en) 2005-02-25
RU2257895C2 (en) 2005-08-10
EE200300340A (en) 2003-10-15
EP1355641A2 (en) 2003-10-29
CZ303665B6 (en) 2013-02-20
DK1355641T3 (en) 2005-10-17
AU2002250869B2 (en) 2006-10-19
CN1561205A (en) 2005-01-05
PL215109B1 (en) 2013-10-31
CA2432432C (en) 2008-03-25
CZ20032095A3 (en) 2004-05-12
JP2004517948A (en) 2004-06-17
KR100857898B1 (en) 2008-09-10
BR0206804A (en) 2004-02-03
ATE304846T1 (en) 2005-10-15
KR20030074725A (en) 2003-09-19
US20040102520A1 (en) 2004-05-27
ITMI20010206A1 (en) 2002-08-02
HUP0303024A3 (en) 2005-07-28
DE60206245D1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
ATE517624T1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCER OF THE BRAIN
EP1350511A4 (en) MEDICAL COMPOSITIONS CONTAINING ASPIRIN
WO2004037193A3 (en) Chromones and chromone derivatives and uses thereof
EP1197210A4 (en) Agents inhibiting chronic rejection reactions after organ transplantation
MXPA03006686A (en) Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs.
EA200000176A1 (en) APPLICATION OF PHYSIOLOGICAL ACCEPTABLE COMPOUNDS, SALTS AND COMPLEXES OF VANADIUM
EP1226822A3 (en) Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same
WO2004018044A3 (en) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent
WO2003024941A1 (en) Naphthalene compounds and use thereof as drugs
WO2002060533A3 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects
JP2004517948A5 (en)
PT1091746E (en) USE OF ISOOSMOTIC SALT SOLUTIONS FOR THE PREPARATION OF CERUMENOLITICAL MEDICINES
EP1236712A4 (en) Amidinophenylpyruvic acid derivative
WO2002062944A2 (en) Novel physiologically active peptide and use thereof
DE59705183D1 (en) THERAPEUTIC AGENTS, CONTAINING LEAVES AGAINST ASTHMA
EP1325918A4 (en) CARDIOUS CELL APOPTOSIS INHIBITORS AND TREATMENT / PREVENTION OF HEART DISEASES
EP1847527A4 (en) Novel benzamidine compound
WO1986006960A3 (en) Use of nicorandil or pinacidil for the treatment of peripheral vascular disease
WO2003039231A3 (en) Compounds and methods for treating transplant rejection
DE502004011865D1 (en) A preparation for the prevention and treatment of acne containing zinc gluconate and copper gluconate
RU2002105061A (en) EYE DROPS
WO1998042312A3 (en) Medicament having sclerosing activity
RU99116456A (en) DRUG FOR PREVENTION AND TREATMENT OF VIRAL ANIMAL DISEASES
PL1755583T3 (en) Use of neboglamine for the treatment of schizophrenia
PL1514545T3 (en) Use of tolperisone for the treatment of spasms of organes consisting essentially of smooth muscles.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003/04861

Country of ref document: ZA

Ref document number: 200304861

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 526655

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2432432

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020037009714

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002719742

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/A/2003/006686

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 028042263

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 9732003

Country of ref document: SK

Ref document number: 157180

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002562337

Country of ref document: JP

Ref document number: PV2003-2095

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2002250869

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020037009714

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10250465

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002719742

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-2095

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 526655

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 526655

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002719742

Country of ref document: EP